Larvol Delta - Neurimmune-and-TVM-Capital-Life-Science-Announce-the-Initiation-of-ALS-Pharmas-Phase-2-Study-of-AP101-for-the-Treatment-of-ALS

AP-101 - AL-S Pharma

https://www.prnewswire.com/news-releases/neurimmune-and-tvm-capital-life-science-announce-the-initiation-of-al-s-pharmas-phase-2-study-of-ap-101-for-the-treatment-of-als-301426737.html

Nov 18, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next